You are here: Industry Insights > Verrica

News List

Verrica Announces FDA Filing Acceptance for VP-102 for Molluscum Contagiosum americanpharmaceuticalreview
February 19, 2021
Verrica Pharmaceuticals announced its resubmitted New Drug Application (NDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted for filing by the ...
Verrica Licenses LTX-315 for Dermatologic Oncology Indications americanpharmaceuticalreview
August 17, 2020
Verrica Pharmaceuticals has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications.
Verrica seeks $86M IPO to take on compounded dermatology drug fiercebiotech
May 29, 2018
Verrica Pharmaceuticals has filed to raise $86 million from public investors. The planned IPO will give Verrica the money it needs to take a treatment for viral skin infection molluscum through phase 3 and onto the market.